A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity

Abstract Background Colorectal cancer (CRC) is one of the most common malignancies and the patient survival rate remains unacceptably low. The anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody-based immune checkpoint inhibitors have been added to CRC treatment regim...

Full description

Bibliographic Details
Main Authors: Lian-sheng Cheng, Yong-feng Cheng, Wen-ting Liu, Aolin Shen, Dayan Zhang, Tingjuan Xu, Wu Yin, Min Cheng, Xiaopeng Ma, Fengrong Wang, Qun Zhao, Xiaoli Zeng, Yan Zhang, Guodong Shen
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Journal of Translational Medicine
Subjects:
4-1BB/CD137
Monoclonal antibody
Targeted therapy
Cancer immunotherapy
Antitumor immunity
Toxicity
Online Access:https://doi.org/10.1186/s12967-022-03619-w

Internet

https://doi.org/10.1186/s12967-022-03619-w

Similar Items